Ampus Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.32 Cr
- Company Age 23 Year, 8 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.05 Cr
- Revenue Growth -48.00%
- Profit Growth -645.25%
- Ebitda 67.10%
- Net Worth -15.82%
- Total Assets -67.86%
About Ampus Life Sciences
Ampus Life Sciences Limited (ALSL) is a Public Limited Indian Non-Government Company incorporated in India on 06 February 2002 and has a history of 23 years. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.32 Cr.
The company currently has active open charges totaling ₹1.05 Cr.
Puneet Mittal, Ansh Mithal, and Raj Kishore serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230MH2002PLC134810
-
Company No.
134810
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
06 Feb 2002
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ampus Life Sciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Puneet Mittal
|
Director | 06-Feb-2002 | Current |
|
Ansh Mithal
|
Director | 10-Aug-2020 | Current |
|
Raj Kishore
|
Director | 03-Jun-2024 | Current |
Financial Performance of Ampus Life Sciences.
Ampus Life Sciences Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 48% decrease. The company also saw a substantial fall in profitability, with a 645.25% decrease in profit. The company's net worth observed a substantial decline by a decrease of 15.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ampus Life Sciences?
In 2023, Ampus Life Sciences had a promoter holding of 76.84% and a public holding of 23.16%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.05 Cr
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.46 Cr
- Icici Bank Limited : 0.34 Cr
- State Bank Of India : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Dec 2013 | Icici Bank Limited | ₹3.41 M | Open |
| 01 Mar 2006 | Canara Bank | ₹4.60 M | Open |
| 13 Jan 2005 | State Bank Of India | ₹2.50 M | Open |
How Many Employees Work at Ampus Life Sciences?
Ampus Life Sciences has a workforce of 5 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ampus Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ampus Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
